License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback